These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 23452312)

  • 41. The role of bromocriptine-QR in the management of type 2 diabetes expert panel recommendations.
    Garber AJ; Blonde L; Bloomgarden ZT; Handelsman Y; Dagogo-Jack S
    Endocr Pract; 2013; 19(1):100-6. PubMed ID: 23337160
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Late phase completed clinical trials investigating bromocriptine mesylate quick release as treatment of type 2 diabetes mellitus.
    Siamashvili M; Davis S
    Expert Opin Pharmacother; 2021 Feb; 22(2):241-247. PubMed ID: 33030357
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Amylin in vasodilation, energy expenditure and inflammation.
    Yang F
    Front Biosci (Landmark Ed); 2014 Jun; 19(6):936-44. PubMed ID: 24896327
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Convergent chemoenzymatic synthesis of a library of glycosylated analogues of pramlintide: structure-activity relationships for amylin receptor agonism.
    Kowalczyk R; Brimble MA; Tomabechi Y; Fairbanks AJ; Fletcher M; Hay DL
    Org Biomol Chem; 2014 Nov; 12(41):8142-51. PubMed ID: 25030939
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Neuroprotective Effects of Amylin Analogues on Alzheimer's Disease Pathogenesis and Cognition.
    Grizzanti J; Corrigan R; Casadesus G
    J Alzheimers Dis; 2018; 66(1):11-23. PubMed ID: 30282360
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dopamine: the forgotten felon in type 2 diabetes.
    Kalra S; Kalra B; Agrawal N; Kumar S
    Recent Pat Endocr Metab Immune Drug Discov; 2011 Jan; 5(1):61-5. PubMed ID: 22074579
    [TBL] [Abstract][Full Text] [Related]  

  • 47. American Diabetes Association--64th Scientific Sessions. Targeting amylin. 4-8 June 2004, Orlando, FL, USA.
    Mazucco RA
    IDrugs; 2004 Jul; 7(7):629-30. PubMed ID: 15243859
    [No Abstract]   [Full Text] [Related]  

  • 48. Glycosylation of pramlintide: synthetic glycopeptides that display in vitro and in vivo activities as amylin receptor agonists.
    Tomabechi Y; Krippner G; Rendle PM; Squire MA; Fairbanks AJ
    Chemistry; 2013 Nov; 19(45):15084-8. PubMed ID: 24123422
    [No Abstract]   [Full Text] [Related]  

  • 49. Modulation of monoaminergic neural circuits: potential for the treatment of type 2 diabetes mellitus.
    Pijl H; Edo AM
    Treat Endocrinol; 2002; 1(2):71-8. PubMed ID: 15765623
    [TBL] [Abstract][Full Text] [Related]  

  • 50. New Antidiabetic Therapies: A Paradigm Shift in Type 2 Diabetes Management.
    Koufakis T; Katsiki N; Kotsa K
    Curr Pharm Des; 2021; 27(8):1007. PubMed ID: 33849410
    [No Abstract]   [Full Text] [Related]  

  • 51. Optimizing antidiabetic therapy: Enhancing COVID-19 outcomes for patients with type-2 diabetes.
    Kow CS; Ramachandram DS; Hasan SS
    Ann Endocrinol (Paris); 2023 Dec; 84(6):792. PubMed ID: 37903668
    [No Abstract]   [Full Text] [Related]  

  • 52. Effect of Bromocriptine-QR (a Quick-Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes Subjects.
    J Am Heart Assoc; 2015 Oct; 4(10):e001991. PubMed ID: 26475299
    [No Abstract]   [Full Text] [Related]  

  • 53. Bromocriptine mesylate: FDA-approved novel treatment for type-2 diabetes.
    Mahajan R
    Indian J Pharmacol; 2009 Aug; 41(4):197-8. PubMed ID: 20523873
    [No Abstract]   [Full Text] [Related]  

  • 54. Advances in management of type 1 diabetes mellitus.
    Aathira R; Jain V
    World J Diabetes; 2014 Oct; 5(5):689-96. PubMed ID: 25317246
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hypothyroidism and Diabetes-Related Dementia: Focused on Neuronal Dysfunction, Insulin Resistance, and Dyslipidemia.
    Kim HK; Song J
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328405
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Role of ketone bodies in diabetes-induced dementia: sirtuins, insulin resistance, synaptic plasticity, mitochondrial dysfunction, and neurotransmitter.
    Chung JY; Kim OY; Song J
    Nutr Rev; 2022 Mar; 80(4):774-785. PubMed ID: 34957519
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Chemical Glycosylation and Its Application to Glucose Homeostasis-Regulating Peptides.
    Chandrashekar C; Hossain MA; Wade JD
    Front Chem; 2021; 9():650025. PubMed ID: 33912539
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dissecting Sex-Related Cognition between Alzheimer's Disease and Diabetes: From Molecular Mechanisms to Potential Therapeutic Strategies.
    Ashraf GM; Ebada MA; Suhail M; Ali A; Uddin MS; Bilgrami AL; Perveen A; Husain A; Tarique M; Hafeez A; Alexiou A; Ahmad A; Kumar R; Banu N; Najda A; Sayed AA; Albadrani GM; Abdel-Daim MM; Peluso I; Barreto GE
    Oxid Med Cell Longev; 2021; 2021():4572471. PubMed ID: 33747345
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A co-formulation of supramolecularly stabilized insulin and pramlintide enhances mealtime glucagon suppression in diabetic pigs.
    Maikawa CL; Smith AAA; Zou L; Roth GA; Gale EC; Stapleton LM; Baker SW; Mann JL; Yu AC; Correa S; Grosskopf AK; Liong CS; Meis CM; Chan D; Troxell M; Maahs DM; Buckingham BA; Webber MJ; Appel EA
    Nat Biomed Eng; 2020 May; 4(5):507-517. PubMed ID: 32393892
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Brain signaling systems in the Type 2 diabetes and metabolic syndrome: promising target to treat and prevent these diseases.
    Shpakov AO; Derkach KV; Berstein LM
    Future Sci OA; 2015 Nov; 1(3):FSO25. PubMed ID: 28031898
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.